公开(公告)号：WO2004001045A1

公开(公告)日：2003-12-31

申请号：PCT/EP2003/006183

申请日：2003-06-12

Applicant: ROCHE VITAMINS AG ,  BENDIK, Igor ,  HEIM, Manuel

Inventor： BENDIK, Igor ,  HEIM, Manuel

IPC: C12N15/11

CPC classification number: C12N15/1138 ,  A01K2217/075 ,  A61K38/00 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2799/021

Abstract: The present invention relates to a method of inhibiting expression of a nuclear receptor gene in a mammalian cell or tissue by introduction of a sense strand and corresponding antisense strand RNA sequence of about 21 to about 23 nucleotides complementary to a part of the receptor mRNA into such cell or tissue, to the 21 - 23 nt nucleotides themselves and corresponding transfer systems and their uses in the preparation of pharmaceutical compositions useful in the treatment of diseases caused by altered expression of the nuclear receptor gene. The invention also relates to a method of examining the function of a mammalian nuclear receptor gene in a cell or tissue.

Abstract translation: 本发明涉及一种抑制哺乳动物细胞或组织中核受体基因表达的方法，方法是将有义链和对应的反义链RNA序列与受体mRNA的一部分互补的约21至约23个核苷酸引入到 细胞或组织，21-23个核苷酸本身和相应的转移系统及其在制备用于治疗由核受体基因表达改变引起的疾病的药物组合物中的用途。 本发明还涉及一种检查哺乳动物核受体基因在细胞或组织中的功能的方法。

公开(公告)号：WO2008110824A2

公开(公告)日：2008-09-18

申请号：PCT/GB2008/000917

申请日：2008-03-14

Applicant: DSM IP ASSETS B.V. ,  WRIGHT, Simon, Mark ,  BENDIK, Igor ,  SANCAK, Ozgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

Inventor： BENDIK, Igor ,  SANCAK, Ozgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/172

Abstract: A method of prevention of age-related macular degeneration (AMD) is provided where a sample is taken from an individual and the presence of a polymorphism associated with a dehydrogenase, oxygenase, acyltransferase, dismutase or a macular or retinal pigment, or an SNP as shown in Table 1 of the specification, is detected. The individual can then be provided with a substance that can prevent or treat AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual.

Abstract translation: 提供了一种预防年龄相关性黄斑变性（AMD）的方法，其中取自个体的样品和与脱氢酶，加氧酶，酰基转移酶，岐化酶或黄斑或视网膜色素或SNP相关的多态性的存在或作为 检测了表1中所示的规格。 然后可以向个体提供可以预防或治疗AMD的物质，或者可以减轻或缓解AMD的症状。 该物质是包含叶黄素和/或玉米黄质的药物和/或某些抗氧化剂（或其混合物）适合于该个体。

公开(公告)号：WO2008110824A3

公开(公告)日：2009-03-26

申请号：PCT/GB2008000917

申请日：2008-03-14

Applicant: DSM IP ASSETS BV ,  WRIGHT SIMON MARK ,  BENDIK IGOR ,  SANCAK OZGUER ,  SCHALCH WOLFGANG ,  WITTWER JONAS

Inventor： BENDIK IGOR ,  SANCAK OZGUER ,  SCHALCH WOLFGANG ,  WITTWER JONAS

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/172

Abstract: A method of prevention of age-related macular degeneration (AMD) is provided where a sample is taken from an individual and the presence of a polymorphism associated with a dehydrogenase, oxygenase, acyltransferase, dismutase or a macular or retinal pigment, or an SNP as shown in Table 1 of the specification, is detected. The individual can then be provided with a substance that can prevent or treat AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual.

Abstract translation: 提供了一种预防年龄相关性黄斑变性（AMD）的方法，其中取自个体的样品和与脱氢酶，加氧酶，酰基转移酶，岐化酶或黄斑或视网膜色素或SNP相关的多态性的存在或作为 检测了表1中所示的规格。 然后可以向个体提供可以预防或治疗AMD的物质，或者可以减轻或缓解AMD的症状。 该物质是包含叶黄素和/或玉米黄质的药物和/或某些抗氧化剂（或其混合物）适合于该个体。

公开(公告)号：WO2008110283A2

公开(公告)日：2008-09-18

申请号：PCT/EP2008/001688

申请日：2008-03-04

Applicant: DSM IP ASSETS B.V. ,  BENDIK, Igor ,  SANCAK, Özgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

Inventor： BENDIK, Igor ,  SANCAK, Özgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

CPC classification number: C12Q1/6886 ,  C12Q2600/172

Abstract: A method of prevention of age-related macular degeneration (AMD) involves, in a first step, taking a sample from an individual and detecting the presence of a polymorphism (rsl 1200638 or rs 10490924, or an SNP related to or associated with a (high temperature requirement) serine protease). In a second step the individual is provided with a substance that can prevent AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining the substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) by detecting the presence of the polymorphism and identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

Abstract translation: 预防年龄相关性黄斑变性（AMD）的方法涉及在第一步中从个体取样并检测多形性（rs1200638或rs10490924，或与（或 高温要求）丝氨酸蛋白酶）。 在第二步中，个体被提供可以预防AMD的物质，或者可以减轻或缓解AMD的症状。 该物质是包含叶黄素和/或玉米黄质的药物和/或某些抗氧化剂（或其混合物）适合于该个体。 本发明还提供了一种确定要给予个体的物质的方法，该个体可能通过检测多态性的存在并鉴定其可能具有年龄相关性黄斑变性（或年龄相关性黄斑变性相关病症） 能够预防或治疗该个体年龄相关性黄斑变性的物质。 该方法可以另外包括向个体提供（例如管理或通信）物质（或其身份）。

公开(公告)号：WO2008110828A1

公开(公告)日：2008-09-18

申请号：PCT/GB2008/000925

申请日：2008-03-14

Applicant: DSM IP ASSETS B.V. ,  WRIGHT, Simon, Mark ,  BENDIK, Igor ,  SANCAK, Özgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

Inventor： BENDIK, Igor ,  SANCAK, Özgür ,  SCHALCH, Wolfgang ,  WITTWER, Jonas

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/172

Abstract: A method of prevention of age-related macular degeneration (AMD) involves, in a first step, taking a sample from an individual and detecting the presence of a polymorphism (rsl 1200638 or rs 10490924, or an SNP related to or associated with a (high temperature requirement) serine protease). In a second step the individual is provided with a substance that can prevent AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining the substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) by detecting the presence of the polymorphism and identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

Abstract translation: 预防年龄相关性黄斑变性（AMD）的方法包括，在第一步中，从个体取样品并检测多态性（rs1112638或rs10490924或 与（高温需求）丝氨酸蛋白酶相关或相关的SNP）。 在第二步中，向个体提供能够预防AMD的物质，或者可以缓解或缓解AMD的症状。 该物质是含有叶黄素和/或玉米黄质和/或某种抗氧化剂（或其混合物）的个体的药物。 本发明还提供了测定待施用于个体的物质的方法，所述个体可能通过检测多态性的存在并鉴定出与年龄相关的黄斑变性（或与年龄相关的黄斑变性有关的病症） 能够预防或治疗该个体的年龄相关性黄斑变性的物质。 该方法可以另外包括向个体提供（例如给予或传递）物质（或其身份）。

公开(公告)号：WO2007029008A3

公开(公告)日：2007-03-15

申请号：PCT/GB2006/003331

申请日：2006-09-08

Applicant: DSM IP ASSETS B.V. ,  WRIGHT, Simon, Mark ,  GORALCZYC, Regina ,  DE SAIZIEU, Antoine ,  SCHALCH, Wolgfang ,  BENDIK, Igor

Inventor： GORALCZYC, Regina ,  DE SAIZIEU, Antoine ,  SCHALCH, Wolgfang ,  BENDIK, Igor

IPC: A61K31/047 ,  A61K31/375 ,  A61K31/355 ,  A61K33/30 ,  A61K33/34 ,  A61P27/02

Abstract: A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

公开(公告)号：WO2007029008A2

公开(公告)日：2007-03-15

申请号：PCT/GB2006003331

申请日：2006-09-08

Applicant: DSM IP ASSETS BV ,  WRIGHT SIMON MARK ,  GORALCZYC REGINA ,  DE SAIZIEU ANTOINE ,  SCHALCH WOLGFANG ,  BENDIK IGOR

Inventor： GORALCZYC REGINA ,  DE SAIZIEU ANTOINE ,  SCHALCH WOLGFANG ,  BENDIK IGOR

CPC classification number: A61K33/34 ,  A61K31/047 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00

Abstract: A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

Abstract translation: 一种治疗和/或预防年龄相关性黄斑变性（AMD）的方法，其中在第一步骤中，对个体确定对AMD的治疗或易感性的需要，并且在第二步骤中，包含叶黄素和/ 或玉米黄质和/或某些抗氧化剂（或其混合物）适合该个体。 本发明还提供了确定待给予个体的物质的方法，该个体可能易患有年龄相关性黄斑变性（或年龄相关性黄斑变性相关病症），其包括：a）确定 个体对年龄相关性黄斑变性（通常在遗传上，通过检测SNP）; 和b）基于a）中确定的物质，鉴定能够预防或治疗该个体年龄相关性黄斑变性的物质。 该方法可以另外包括向个体提供（例如管理或通信）物质（或其身份）。